COMBINATORIC: Carbon Ion Boost With Photons or Protons in Salivary Gland and Sinonasal Cancers.

IF 2.9 3区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral diseases Pub Date : 2025-09-09 DOI:10.1111/odi.70086

Anna Maria Camarda, Giulia Fontana, Barbara Vischioni, Amelia Barcellini, Maria Bonora, Jessica Franzetti, Nadia Facchinetti, Federica Serra, Carmine Tinelli, Rossana Ingargiola, Sara Ronchi, Viviana Vitolo, Pierluigi Bonomo, Sara Colombo, Daniela Alterio, Nicola Alessandro Iacovelli, Marzia Franceschini, Giovanni Ivaldi, Marco Trovò, Elisa D'Angelo, Ester Orlandi

{"title":"COMBINATORIC: Carbon Ion Boost With Photons or Protons in Salivary Gland and Sinonasal Cancers.","authors":"Anna Maria Camarda, Giulia Fontana, Barbara Vischioni, Amelia Barcellini, Maria Bonora, Jessica Franzetti, Nadia Facchinetti, Federica Serra, Carmine Tinelli, Rossana Ingargiola, Sara Ronchi, Viviana Vitolo, Pierluigi Bonomo, Sara Colombo, Daniela Alterio, Nicola Alessandro Iacovelli, Marzia Franceschini, Giovanni Ivaldi, Marco Trovò, Elisa D'Angelo, Ester Orlandi","doi":"10.1111/odi.70086","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the outcomes of combining carbon ion radiotherapy boost (CIRTb) with photons (Ph) or protons (PT) for locally advanced salivary gland and sinonasal cancers (SGCs and SNCs).Materials and methods: Sixty-nine patients with SGCs and SNCs received CIRTb to high-risk CTV and Ph or PT to low-risk CTV (LR-CTV) from October 2014 to September 2022. Two-year local relapse-free survival (LRFS) was analyzed with Kaplan-Meier. Toxicity according to Common Terminology Criteria for Adverse Events v5. Variables affecting toxicities were analyzed with chi-squared and Mann-Whitney U tests.Results: Patients received a median CIRTb dose of 15 Gy RBE, with 29 (41%) receiving Ph and 42 (59%) receiving PT. With a median follow-up of 17.23 months, 2-year LRFS achieved 87.8% (95% CI: 79.6-96.8). Female (p = 0.045) reported better 2-year LRFS rates: 95.2% (95% CI: 86.6-100) versus 81.8% (95% CI: 69.5-96.2). Acute and late G2+ toxicity were, respectively, 80% and 60%. Ph (p = 0.004) and smaller LR-CTV (p = 0.004) reduced acute and late toxicities. No G4 late toxicity was reported.Conclusions: CIRT combined with Ph or PT seems a valuable option for locally advanced SGCs and SNCs. Prospective studies are needed to select the best treatment combination.","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.70086","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate the outcomes of combining carbon ion radiotherapy boost (CIRTb) with photons (Ph) or protons (PT) for locally advanced salivary gland and sinonasal cancers (SGCs and SNCs).

Materials and methods: Sixty-nine patients with SGCs and SNCs received CIRTb to high-risk CTV and Ph or PT to low-risk CTV (LR-CTV) from October 2014 to September 2022. Two-year local relapse-free survival (LRFS) was analyzed with Kaplan-Meier. Toxicity according to Common Terminology Criteria for Adverse Events v5. Variables affecting toxicities were analyzed with chi-squared and Mann-Whitney U tests.

Results: Patients received a median CIRTb dose of 15 Gy RBE, with 29 (41%) receiving Ph and 42 (59%) receiving PT. With a median follow-up of 17.23 months, 2-year LRFS achieved 87.8% (95% CI: 79.6-96.8). Female (p = 0.045) reported better 2-year LRFS rates: 95.2% (95% CI: 86.6-100) versus 81.8% (95% CI: 69.5-96.2). Acute and late G2+ toxicity were, respectively, 80% and 60%. Ph (p = 0.004) and smaller LR-CTV (p = 0.004) reduced acute and late toxicities. No G4 late toxicity was reported.

Conclusions: CIRT combined with Ph or PT seems a valuable option for locally advanced SGCs and SNCs. Prospective studies are needed to select the best treatment combination.

查看原文本刊更多论文

组合：碳离子与光子或质子促进唾液腺和鼻窦癌。

目的：评价碳离子放疗增强（CIRTb）联合光子（Ph）或质子（PT）治疗局部晚期唾液腺和鼻窦癌（SGCs和SNCs）的疗效。材料与方法：2014年10月至2022年9月，69例SGCs和SNCs患者接受CIRTb至高危CTV， Ph或PT至低危CTV （LR-CTV）。Kaplan-Meier法分析2年局部无复发生存率（LRFS）。根据不良事件通用术语标准v5的毒性。用卡方检验和Mann-Whitney U检验分析影响毒性的变量。结果：患者接受的中位CIRTb剂量为15 Gy RBE，其中29例（41%）接受Ph治疗，42例（59%）接受PT治疗。中位随访时间为17.23个月，2年LRFS达到87.8% （95% CI: 79.6-96.8）。女性（p = 0.045）报告了更好的2年LRFS率：95.2% （95% CI: 86.6-100）对81.8% （95% CI: 69.5-96.2）。急性和晚期G2+毒性分别为80%和60%。Ph （p = 0.004）和较小的LR-CTV （p = 0.004）降低了急性和晚期毒性。未见G4晚期毒性报道。结论：CIRT联合Ph或PT似乎是局部晚期SGCs和SNCs的有价值的选择。需要前瞻性研究来选择最佳的治疗组合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral diseases 医学-牙科与口腔外科

CiteScore

7.60

自引率

5.30%

发文量

325

审稿时长

4-8 weeks

期刊介绍： Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.